Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-12-13 pm EST			5-day change	1st Jan Change
789.12 ^USD	+0.87%		-4.42%	+35.37%

06:00pm	EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly	RE
05:00pm	European Medicines Agency: Sleep Apnea Label for Lilly's Mounjaro 'Not Needed'	MT

Viking Obesity Data Suggests Pill Can Compete With Shots

November 04, 2024 at 11:18 am EST

Viking Therapeutics released new data on an obesity pill that may eventually compete with blockbuster shots from Eli Lilly (LLY) and Novo Nordisk (NVO), stoking further takeout speculation for the company. Michael Shah of Bloomberg Intelligence has more on Bloomberg Television.

Bloomberg videos, provided by MT Newswires

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ELI LILLY AND COMPANY	789.12USD	+0.87%	-4.42%	704B
NOVO NORDISK A/S	754.00DKK	-3.89%	-2.20%	488B
VIKING THERAPEUTICS, INC.	47.03USD	-1.75%	-5.71%	5.33B

Latest news about Eli Lilly and Company

EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly	12:00pm	RE
European Medicines Agency: Sleep Apnea Label for Lilly's Mounjaro 'Not Needed'	11:00am	MT
EU Panel Backs Eli Lilly's Crohn's Disease Treatment	10:58am	MT
Eli Lilly: positive EU opinion for Crohn's disease	10:43am	CF
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says	10:05am	MT
Eli Lilly's Omvoh Recommended by European Medicine Agency as Crohn's Disease Treatment	08:48am	MT
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease	08:48am	DJ
UK's private obesity drug market chooses Lilly's Mounjaro over Wegovy	07:59am	RE
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market	01:04am	RE
Adocia and Tonghua Dongbao Pharmaceutical Co. Ltd Announce the Final Dosing in A Phase 3 Clinical Study of Biochaperone®? Lispro	Dec. 12	CI
Eli Lilly: imlunestrant shows promise in breast cancer	Dec. 12	CF
Rubenstein on Lilly, New FTC Head, Library of Congress	Dec. 11	MT
Swiss Market Index Recovers Ahead of Interest Rate Decision	Dec. 11	MT
Eli Lilly's Breast Cancer Drug Cuts Disease Progression, Improves Survival in Late-stage Trial	Dec. 11	MT
Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials	Dec. 11	MT
Eli Lilly Teams Up With Ro for Single-dose Vials of Obesity Drug	Dec. 11	MT
Eli Lilly Says Imlunestrant Improved Progression-Free Survival in Phase 3 Breast Cancer Study	Dec. 11	MT
Eli Lilly and Company Announces Results from the Phase 3 Ember-3 Study of Imlunestrant	Dec. 11	CI
Ro Works with Lilly to Streamline Patient Access to Authentic Zepbound® Single-Dose Vials by Integrating with Lilly's Pharmacy Channel	Dec. 11	CI
Lilly Will Test Obesity Drugs on Addiction, CEO Says	Dec. 10	MT
Eli Lilly: further share buybacks and dividend increase	Dec. 10	CF
Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment	Dec. 10	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Dec. 10	MT
Eli Lilly Says Late-Stage Study Evaluating Pirtobrutinib Meets Primary Endpoint	Dec. 10	MT
Eli Lilly's Board Approves New $15 Billion Share Buyback	Dec. 09	MT

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

06:30pm - San Antonio Breast Cancer Symposium - Presentation No.: P4-12-24

More about the company